On June 23rd, Ennovation Ventures invested company TransThera Sciences （Nanjing）,Inc. was officially listed on the main board of the Hong Kong Stock Exchange, with the company code 02617.HK.
TransThera is a biopharmaceutical company guided by clinical needs and in the registered clinical stage, focusing on discovering and developing innovative small molecule therapies for tumors, inflammation, and cardiovascular metabolic diseases. With its fully integrated internal "ACE" R&D platform, the company has established a pipeline of six clinical stage candidate products and one preclinical stage candidate product, and plans to continue expanding. The company focuses on developing similar pioneering or best candidate drugs with significant clinical value to meet unmet clinical needs worldwide.
The core product of the company, Tinengotinib, is a unique multi-target kinase inhibitor that has the potential to become the world's first heavyweight drug, is in the registration clinical stage, and is independently developed. Currently, Tinengotinib is undergoing two critical/registered clinical trials for the treatment of cholangiocarcinoma patients who have experienced disease progression after previous treatment with FGFR inhibitors. In addition, the company is exploring the use of this drug in the treatment of metastatic castration resistant prostate cancer, breast cancer, biliary system cancer and pan FGFR solid tumors, and has completed the phase II clinical study of these indications.
There is a clear unmet clinical need in the treatment of cholangiocarcinoma and metastatic castration resistant prostate cancer. Tinengotinib, independently developed by Yaojie Ankang, has shown significant clinical therapeutic potential in multiple indications, and its unique mechanism of action is expected to provide new treatment options for the above-mentioned refractory tumors. This landing in the capital market is an important milestone for the company's development and a new starting point for globalization. The company will accelerate the clinical research and development process of differentiated and high-value innovative drug management lines, committed to growing into an internationally competitive innovative pharmaceutical enterprise and injecting more vitality into the field of precision cancer treatment.
